ENA 002
Alternative Names: ENA-002Latest Information Update: 28 Oct 2025
At a glance
- Originator Enalare Therapeutics
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Respiration disorders; Sleep apnoea syndrome; Unspecified
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
- 28 Oct 2025 No recent reports of development identified for preclinical development in Respiration-disorders in USA
- 28 Oct 2025 No recent reports of development identified for preclinical development in Sleep-apnoea-syndrome in USA